

## MAGNESIUM

**PRESENTATION:** Ampoules containing magnesium sulphate 50% equivalent to 2mmol/ml: 10ml ampoules.

**INDICATION:** Correction of hypomagnesaemia. Normal range: 0.7 – 1.0 mmol/l.  
Treatment of hypomagnesaemia associated with arrhythmias.  
Severe bronchospasm.

**DOSE AND ADMINISTRATION:** **ICU STANDARD INTRAVENOUS INFUSION**

**For treatment of hypomagnesaemia:**

**Peripheral administration:**

20mmol in 250ml glucose 5% over 4 hours.

**Central administration:**

20mmol in 100ml glucose 5% over 4 hours.

**For treatment of severe acute asthma:**

8mmol (2g) in 50mls glucose 5% over 20 minutes, peripherally or centrally.

**For treatment of serious arrhythmias:**

8mmol (2g) in 50mls glucose 5% over 20 minutes, peripherally or centrally. Dose may be repeated once if necessary.

**STABILITY:** Physically and chemically stable for 24 hours at room temperature.

**ADDITIONAL NOTES:** Also stable in sodium chloride 0.9%.

### References

1. Norohna J et al. Magnesium in critical illness: metabolism, assessment and treatment. Intensive Care Medicine 2002;28:667-79.
2. Magnesium sulphate 50% Injection. Summary of Product Characteristics. Martindale Pharma. Last updated 25/09/20. <https://www.medicines.org.uk/emc/product/3539/smpc> .Accessed 21/10/20.
3. Magnesium sulphate. Version 10. The UK Injectable Medicines Guide. Accessed 21/10/20.
4. BNF App, Version 3.0.1. Updated 02/09/20.
5. NHS Lothian University Hospitals Division-Adult Medical Emergencies Handbook. 2009/2011.

<b>Title:</b> Magnesium	
<b>ID:</b> TOPG140612v1	<b>Lead Author:</b> Claire Hannah
<b>Category:</b> 1	<b>Document Version;</b> 4
<b>Status Draft/Final:</b> Final	<b>Review Date:</b> October 2022
<b>Authoriser;</b> Lothian Critical Care Directorate Editorial Board.	<b>Date Authorisation:</b> October 2020
<b>Date added to intranet:</b> November 2020	
<b>Key Words;</b>	
<b>Comments;</b>	

**Critical Care Guidelines  
OR CRITICAL CARE USE ONLY**